

## Appendix 1. PRISMA-P 2015 Checklist

Section/topic	#	Checklist item	Information reported		Line number(s)
			Yes	No	
<b>ADMINISTRATIVE INFORMATION</b>					
<b>Title</b>					
Identification	1a	Identify the report as a protocol of a systematic review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	1, 27, 47, 65, 99
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	<input checked="" type="checkbox"/>	<input type="checkbox"/>	94
<b>Registration</b>	2	If registered, provide the name of the registry (e.g., PROSPERO) and registration number in the Abstract	<input checked="" type="checkbox"/>	<input type="checkbox"/>	36, 112
<b>Authors</b>					
Contact	3a	Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical mailing address of corresponding author	<input checked="" type="checkbox"/>	<input type="checkbox"/>	5-14
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	324-328
<b>Amendments</b>	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	<input type="checkbox"/>	<input checked="" type="checkbox"/>	N/A
<b>Support</b>					
Sources	5a	Indicate sources of financial or other support for the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	330-337
Sponsor	5b	Provide name for the review funder and/or sponsor	<input checked="" type="checkbox"/>	<input type="checkbox"/>	330-337
Role of sponsor/funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	<input checked="" type="checkbox"/>	<input type="checkbox"/>	336-337
<b>INTRODUCTION</b>					
<b>Rationale</b>	6	Describe the rationale for the review in the context of what is already known	<input checked="" type="checkbox"/>	<input type="checkbox"/>	94-97
<b>Objectives</b>	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	103-107
<b>METHODS</b>					
<b>Eligibility criteria</b>	8	Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	132-149
<b>Information sources</b>	9	Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage	<input checked="" type="checkbox"/>	<input type="checkbox"/>	121-130
<b>Search strategy</b>	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Appendix 2

Section/topic	#	Checklist item	Information reported		Line number(s)
			Yes	No	
<b>STUDY RECORDS</b>					
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	200-208
Selection process	11b	State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	191-198
Data collection process	11c	Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	<input checked="" type="checkbox"/>	<input type="checkbox"/>	200-208
<b>Data items</b>	12	List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications	<input checked="" type="checkbox"/>	<input type="checkbox"/>	205-207
<b>Outcomes and prioritization</b>	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	<input checked="" type="checkbox"/>	<input type="checkbox"/>	163-169
<b>Risk of bias in individual studies</b>	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	<input checked="" type="checkbox"/>	<input type="checkbox"/>	210-218
<b>DATA</b>					
<b>Synthesis</b>	15a	Describe criteria under which study data will be quantitatively synthesized	<input checked="" type="checkbox"/>	<input type="checkbox"/>	245-256
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., $I^2$ , Kendall's tau)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	220-226, 236-242, 245-256
	15c	Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-regression)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	258-266
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	<input type="checkbox"/>	<input checked="" type="checkbox"/>	N/A
<b>Meta-bias(es)</b>	16	Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective reporting within studies)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	241-242
<b>Confidence in cumulative evidence</b>	17	Describe how the strength of the body of evidence will be assessed (e.g., GRADE)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	245-246

**Appendix 2: MEDLINE Ovid search strategy**

1. exp eye diseases/
2. Visually Impaired Persons/
3. ((low\$ or handicap\$ or subnormal\$ or impair\$ or partial\$ or disab\$ or disorder\$ or loss\$ or limit\$) adj3 (vision or visual\$ or sight\$)).tw.
4. ((macul\$ or retina\$ or choroid\$) adj3 degener\$).tw.
5. ((macul\$ or retina\$ or choroid\$) adj3 neovasc\$).tw.
6. (AMD or ARMD).tw.
7. ((diabet\$ or proliferative or non-proliferative or pre-proliferative) adj4 retinopath\$).tw.
8. (diabet\$ adj2 (eye\$ or vision or visual\$ or sight\$)).tw.
9. glaucoma\$.tw.
10. cataract\$.tw.
11. blindness.tw.
12. Visual Acuity/
13. visual acuit\$.tw.
14. Contrast Sensitivity/
15. (contrast adj2 sensitivity).tw.
16. Depth Perception/
17. stereopsis.tw.
18. (stereo adj1 acuit\$).tw.
19. Visual Fields/
20. ((visual\$ or vision) adj2 function\$).tw.
21. or/1-20
22. exp Mortality/
23. Death Certificates/
24. mortality.tw.
25. death\$.tw.
26. (fatality or fatalities).tw.
27. or/22-26
28. Cohort Studies/
29. Longitudinal Studies/
30. (cohort\$ or longitudinal).tw.
31. Cross-Sectional Studies/
32. "Surveys and Questionnaires"/
33. Health Surveys/
34. (survey or surveys).tw.
35. or/28-34
36. 21 and 27 and 35
37. (neonate\$ or preterm\$ or prematurity or infant\$ or child\$).tw.
38. visual analog\$ scale.tw.
39. (case adj2 report\$).tw.
40. (animal or mouse or mice or rat or rats).ti.
41. or/37-40
42. 36 not 41